Trial Profile
A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs QBM 076 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 23 Mar 2016 No of arms changed from 10 to 6 as per ClinicalTrials.gov record.
- 29 Sep 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 29 Aug 2014 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov record.